AstraZeneca PLC (AZNCF)

Market Cap	229.50B
Revenue (ttm)	54.07B
Net Income (ttm)	7.04B
Shares Out	n/a
EPS (ttm)	4.50
PE Ratio	32.62
Forward PE	n/a
Dividend	3.10 (2.18%)
Ex-Dividend Date	Feb 20, 2025

Volume	800
Average Volume	2,165
Open	144.00
Previous Close	146.50
Day's Range	142.40 - 146.50
52-Week Range	120.64 - 175.00
Beta	0.20
RSI	50.82
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.